Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761914 · ClinicalTrials.gov registry record · Phase 1
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
A Phase 1 study, sponsored by Sellas Life Sciences Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03761914 is a Phase 1 study that has completed, run by Sellas Life Sciences Group. The registered enrollment target is 26 participants.
The verdict
NCT03761914, a Phase 1 study, has completed, sponsored by Sellas Life Sciences Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
Interventions
- BIOLOGICAL pembrolizumab
- BIOLOGICAL GM-CSF
- OTHER Montanide
- BIOLOGICAL galinpepimut-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761914
The ClinicalTrials.gov registry entry for NCT03761914 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sellas Life Sciences Group, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pembrolizumab is the first listed.
NCT03761914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03761914 about?
NCT03761914 is a clinical study titled "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers". To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
What is the current status of trial NCT03761914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2019-09-30. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT03761914?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), GM-CSF (BIOLOGICAL), Montanide (OTHER), galinpepimut-S (BIOLOGICAL).
Who is sponsoring clinical trial NCT03761914?
This trial is sponsored by Sellas Life Sciences Group, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.